J. Dowd

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

M. Geyer, G. Inghirami, S. Horwitz, 2021, Blood.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.